Fairmount Funds Management LLC 13D/13G Filings for Enliven Therapeutics, Inc. (ELVN)

Fairmount Funds Management LLC 13D and 13G filings for Enliven Therapeutics, Inc.:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Shares have been adjusted for stock splits.
Time period
Reported
DateTime
Transaction
Date
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportView
2024-11-14
4:15 pm
Purchase
2024-09-3013GEnliven Therapeutics, Inc.
ELVN
Fairmount Funds Management LLC3,202,798
6.800%
1,071,429increase
(+50.27%)
Filing
2024-02-14
3:45 pm
Purchase
2023-12-3113GEnliven Therapeutics, Inc.
ELVN
Fairmount Funds Management LLC2,131,369
5.200%
6,744increase
(+0.32%)
Filing
2023-04-27
10:00 am
Purchase
2023-04-1813GEnliven Therapeutics, Inc.
ELVN
Fairmount Funds Management LLC2,124,625
5.170%
2,124,625increase
(New Position)
Filing